Prostaplant has anti-androgenic, anti-inflammatory and anti-edema effects, which is selectively directed to the prostate gland.
Antiandrogenic activity of the drug is due to inhibition of the enzyme 5-alpha-reductase. Under the influence of this enzyme entering the prostate gland testosterone turns into an active form - di-hydrotestosterone. The prostaplant prevents the formation of a di-hydrotestosterone-receptor complex, its penetration into the nucleus of the cell, and subsequent inducing of protein synthesis. As a result, proliferative changes in the tissues of the prostate gland are inhibited. Prostaplant does not affect the levels of testosterone, follicle-stimulating and lyutenizing hormones in the blood plasma in men.
Anti-inflammatory and anti-swelling effects of the drug are associated with inhibition of the enzyme cyclooxygenase and 5-lipoxygenase.
Prostaplant reduces capillary permeability and vascular stasis, relieves edema and inflammation of the prostate, thus eliminating compression on the neck of the urinary bladder and urethra, improves the urodynamics of the urinary tract.
These properties of the drug contribute to the reduction of specific symptoms of prostatic hyperplasia, such as dysuria, pollakuriya, nocturia, a decrease in the volume and strength of urination, incomplete emptying of the bladder, pain and a feeling of tension in the perineum on I-II stage of the disease. Prostaplant does not reduce the potency in men, does not affect the level of the prostatic specific antigen (PSA) in the blood plasma.